(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
04 November 2021 (04.11.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/220185 A1

(51) International Patent Classification:
C07D 471/04 (2006.01) *A61P 35/00* (2006.01)
C07D 519/00 (2006.01) *A61K 31/437* (2006.01)

(21) International Application Number:
PCT/IB2021/053522

(22) International Filing Date:
28 April 2021 (28.04.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/018,689 01 May 2020 (01.05.2020) US

(71) Applicant: **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, New York 10017 (US).

(72) Inventors: **BARBER, Joyann**; c/o Pfizer Inc., 10777 Science Center Drive, San Diego, California 92121 (US). **CHO-SCHULTZ, Sujin**; c/o Pfizer Inc., 10777 Science Center Drive, San Diego, California 92121 (US). **DEL BEL, Matthew L**; c/o Pfizer Inc., 10777 Science Center Drive, San Diego, California 92121 (US). **GALLEGO, Rebecca Anne**; c/o Pfizer Inc., 10777 Science Center Drive, San Diego, California 92121 (US). **HE, Mingying**; c/o Pfizer Inc., 10777 Science Center Drive, San Diego, California 92121 (US). **JALAIE, Mehran**; c/o Pfizer Inc., 10777 Science Center Drive, San Diego, California 92121 (US). **KANIA, Robert Steven**; 13796 Nogales Drive, Del Mar, California 92014 (US). **MCTIGUE, Michele Ann**; c/o Pfizer Inc., 10777 Science Center Drive, San Diego, California 92121 (US). **NAIR, Sajiv Krishnan**; c/o Pfizer Inc., 10777 Science Center Drive, San Diego, California 92121 (US). **SCHMITT, Anne-Marie Dechert**; c/o Pfizer Inc., 445 Eastern Point Road, Bldg. 98, Groton, Connecticut 06340 (US). **TUTTLE, Jamison Bryce**; c/o Pfizer Inc., 610 Main Street, Cambridge, Massachusetts 02139 (US). **ZHOU, Dahui**; c/o Pfizer Inc., 445 Eastern Point Road, Building 98, Groton, Connecticut 06340 (US). **ZHOU, Ru**; c/o Pfizer Inc., 10777 Science Center Drive, San Diego, California 92121 (US).

(74) Agent: **ZIELINSKI, Bryan C.**; Pfizer Inc., 235 East 42nd Street, MS 235/9/86, New York, New York 10017 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

(54) **Title:** AZALACTAM COMPOUNDS AS HPK1 INHIBITORS



(I)

(57) **Abstract:** This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R^1, R^2, R^{3a}, R^{3b}, and R^4 are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

WO 2021/220185 A1